Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 30th Congress of the European Hematology Association (EHA) was held in Milan, Italy, from June 12-15, 2025. This meeting brought together world-leading clinicians and researchers to share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies.

EHA 2025

The 30th Congress of the European Hematology Association (EHA)
12–15 June 2025 | Milan, Italy

EHA 2025

The 30th Congress of the European Hematology Association (EHA)
12–15 June 2025 | Milan, Italy
The 30th Congress of the European Hematology Association (EHA) was held in Milan, Italy, from June 12-15, 2025. This meeting brought together world-leading clinicians and researchers to share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies.
View all videos

Latest Videos

View all videos
3:51
Using luspatercept in patients with β-thalassemia who convert to transfusion dependence late in life
Maria Dimopoulou • 20 Oct 2025
2:26
Outcomes of venetoclax-based therapy in patients with t(11;14) AL amyloidosis
Danai Dima • 24 Jun 2025
3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
1:06
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci • 20 Jun 2025

Multiple Myeloma

View all
1:45
The impact of extramedullary disease on outcomes of CAR T-cell therapy in multiple myeloma
Shambavi Richard • 13 Jun 2025
7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025

Acute Myeloid Leukemia

View all
6:43
The Phase III QuANTUM-Wild trial: quizartinib in newly diagnosed FLT3-ITD-negative AML
Harry Erba • 12 Jun 2025
2:00
Prolonging remission in AML: stem cell transplantation or continuous treatment
Gail Roboz • 14 Jun 2025

Chronic Lymphocytic Leukemia

View all
3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
5:35
Fixed-duration versus continuous treatment of venetoclax-based regimens in CLL
Jacqueline Barrientos • 19 Jun 2025

Myeloproliferative Neoplasms

View all
2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
2:45
An indirect comparison of the safety profiles of JAK inhibitors in patients with myelofibrosis
Lucia Masarova • 12 Jun 2025

Lymphoma

View all
1:06
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci • 20 Jun 2025
1:34
Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam • 10 Jun 2025

Myelodysplastic Syndromes

View all
3:59
The use of immunosuppressive therapy in MDS: available agents and areas for further research
Valeria Santini • 15 Jun 2025
1:14
Luspatercept versus epoetin alfa in the COMMANDS trial: overall survival after two and a half years
Valeria Santini • 15 Jun 2025

Press Briefings

View all
5:00
Incidence and clinical outcomes of erythrocytosis associated with SGLT2 inhibitors
Ji Yun Lee • 13 Jun 2025
4:55
Results from the Phase III POLARGO trial: Pola-R-GemOx vs R-GemOx for R/R DLBCL
Matthew Matasar • 14 Jun 2025
7:23
Clinical characteristics & survival of a large international cohort of patients with MPL-mutant ET
Steffen Koschmieder • 13 Jun 2025
5:26
Targeting SLAMF6 upregulation in AML: development of a novel antibody
Carl Sandén • 13 Jun 2025

Community Focus

View all
1:34
Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam • 10 Jun 2025
7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025

Immuno-Oncology

View all
1:34
Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam • 10 Jun 2025
2:23
Combining chemotherapy, brentuximab vedotin, and nivolumab in advanced-stage Hodgkin’s lymphoma
Maher Salamoon • 14 Jun 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals